other material
confidence high
sentiment positive
materiality 0.85
Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
GENELUX Corp
- SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
- NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.
- Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).
- Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026.